サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1493199

日本のCDMO（医薬品受託開発製造機関）の市場規模、シェア、動向分析レポート：製品タイプ別、ワークフロー別、用途別、国別、セグメント予測、2024年～2030年

Japan Contract Development Manufacturing Organization Market Size, Share & Trends Analysis Report By Product Type, By Workflow, By Application, By Country, And Segment Forecasts, 2024 - 2030

出版日
ページ情報
英文 127 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
日本のCDMO（医薬品受託開発製造機関）の市場規模、シェア、動向分析レポート：製品タイプ別、ワークフロー別、用途別、国別、セグメント予測、2024年～2030年
出版日: 2024年05月08日
発行: Grand View Research
ページ情報: 英文 127 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

日本のCDMO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、日本のCDMO市場は2030年までに194億9,000万米ドルに達すると予測され、2024年から2030年までのCAGRは6.8%と予測されています。

バイオ医薬品需要の増加、疾病負担の増大、高齢者人口の増加が主な成長要因の一部です。様々な医薬品開発・製造受託機関（CDMO）による施設やサービス拡張のための投資の拡大は、予測期間中に市場を押し上げる可能性が高いです。

加えて、製薬企業の研究開発投資の増加が市場成長の原動力となっています。製薬企業は研究開発への投資を増やすにつれ、医薬品開発プロセスを加速するために外部の専門知識やリソースを求めることがあります。CDMOは医薬品開発、製造、検査に特化したサービスを提供するため、研究開発活動の特定の側面を外部委託したいと考えている製薬企業にとっては貴重なパートナーとなっています。複数の企業が医薬品の研究開発活動に投資しています。例えば、WuXi AppTecは2022年3月、細胞治療や遺伝子治療における薬剤用アデノ随伴ウイルスの生産を加速するため、テトラサイクリン対応自己不活性化アデノウイルス（TESSA）技術を発表しました。

製薬企業によるアウトソーシングサービスの増加は、日本市場に大きな影響を与えています。製薬領域におけるアウトソーシング活動の動向は、企業が医薬品開発・商業化の成功に不可欠な付加的能力を獲得することに価値を見出すにつれて高まっています。アウトソーシングは、専門知識の提供やキャッシュフロー管理の改善に加え、投資リスクの軽減など製造面でも大きなメリットをもたらします。

注目すべきは、日本の規制当局が再生医療・遺伝子治療製品の承認を加速させていることです。例えば、医薬品医療機器等法（PMD法）、21世紀医療法（21st Century Cures Act）、PRIME（Priority Medicines）イニシアティブの採用は、日本が再生医療へのアクセスを改善するのに役立っています。規制当局によるこのような取り組みは、同国における再生医療の開発と製造の需要を改善すると期待されています。

日本CDMO市場レポートハイライト

  • 原薬（API）セグメントは2023年に81.2%のシェアで市場を独占しました。同分野の成長を牽引しているのは、競争力のある医薬品開発とエンドツーエンドの開発製造受託機関（CDMO）サービスに対する需要の高まりです。また、原薬製造の進歩、バイオ医薬品分野の成長、高齢者人口の増加なども、同分野の成長を後押しする主な要因となっています。
  • バイオシミラー医薬品、ジェネリック医薬品、再生療法などの旺盛な医薬品需要に起因しています。業務用CDMOは、知識の提供、時間の節約、費用対効果の高さによって、このような場面で役立つ可能性があります。
  • 用途別では、がん領域が2023年に35.3%の売上シェアを占め、検査タイプ市場を独占しました。がん治療用の再生医療製品やウイルス療法の承認は市場の成長をさらに後押しし、このセグメントは世界のがん患者数の増加によってさらに牽引されます。さらに、医薬品の研究開発投資の増加、特許切れ、がん治療薬と生物学的革新技術への需要が、がん分野の成長を促進する要因となっています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 日本のCDMO市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/補助市場見通し
  • 市場力学
    • 市場 促進要因分析
    • 市場抑制要因分析
  • 日本CDMO市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 日本のCDMO市場：製品推定・動向分析

  • 定義と範囲
  • 製品市場シェア、2023年および2030年
  • セグメントダッシュボード
  • 日本のCDMO市場変動分析
  • 日本のCDMO市場規模と動向分析、製品別、2018年から2030年
  • API
  • 医薬品

第5章 日本のCDMO市場：ワークフローの推定・動向分析

  • 定義と範囲
  • セグメントダッシュボード
  • 日本のCDMO市場変動分析
  • 日本のCDMO市場規模と動向分析、ワークフロー別、2018年～2030年
  • 臨床
  • 商業

第6章 日本のCDMO市場：用途の推定・動向分析

  • 定義と範囲
  • セグメントダッシュボード
  • 日本のCDMO市場変動分析
  • 日本のCDMO市場規模と動向分析、用途別、2018年～2030年
  • オンコロジー
  • 感染症
  • 神経障害
  • 循環器疾患
  • 代謝障害
  • 自己免疫疾患
  • 眼科
  • 消化管障害
  • ホルモン障害
  • 血液障害
  • その他

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
  • 市場参入企業の分類
    • 主要販売代理店およびチャネルパートナーのリスト
    • 主要顧客
    • 主要企業の市場シェア分析、2023年
    • Lonza
    • Thermo Fisher Scientific, Inc.
    • Recipharm AB
    • Laboratory Corporation of America Holdings (LabCorp)
    • Catalent, Inc.
    • WuXi AppTec, Inc.
    • Samsung Biologics
    • CordenPharma International
    • Cambrex Corporation
    • Bushu Pharmaceuticals Ltd.
    • CMIC HOLDINGS Co., LTD.
    • Nipro Corporation
    • Sumitomo Chemical Company, Limited
図表

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviations
  • Table 3 Japan CDMO Market, By Product Type, 2018 - 2030 (USD Million)
  • Table 4 Japan CDMO Market, Work Flow Type, 2018 - 2030 (USD Million)
  • Table 5 Japan CDMO Market, By Application, 2018 - 2030 (USD Million)
  • Table 6 ADC Approvals in Japan
  • Table 7 Financial performance
  • Table 8 Key company initiating service launches/upgrades
  • Table 9 Key companies initiating service launches/upgrades
  • Table 10 Key companies initiating partnerships
  • Table 11 Key companies initiating expansion
  • Table 12 Key companies initiating expansion

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Volume price analysis
  • Fig. 9 Japan CDMO market snapshot, 2023 (in USD Million)
  • Fig. 10 Segment snapshot, 2023 & 2030 (USD Million)
  • Fig. 11 Workflow Segment snapshot, 2023 & 2030 (USD Million)
  • Fig. 12 Competitive landscape snapshot
  • Fig. 13 Market dynamics
  • Fig. 14 Risk associated with outsourcing services
  • Fig. 15 Porter's five forces analysis
  • Fig. 16 PESTEL Analysis
  • Fig. 17 Japan CDMO market Product outlook: Segment dashboard
  • Fig. 18 Japan CDMO market: Product movement analysis
  • Fig. 19 API market, 2018 - 2030 (USD Million)
  • Fig. 20 Traditional APIs market, 2018 - 2030 (USD Million)
  • Fig. 21 HP-API market, 2018 - 2030 (USD Million)
  • Fig. 22 Antibody drug conjugate market, 2018 - 2030 (USD Million)
  • Fig. 23 Others market, 2018 - 2030 (USD Million)
  • Fig. 24 Synthetic market, 2018 - 2030 (USD Million)
  • Fig. 25 Solid market, 2018 - 2030 (USD Million)
  • Fig. 26 Liquid market, 2018 - 2030 (USD Million)
  • Fig. 27 No. of Biosimilar approvals (2012-2021)
  • Fig. 28 Biotech market, 2018 - 2030 (USD Million)
  • Fig. 29 Innovative market, 2018 - 2030 (USD Million)
  • Fig. 30 Generics market, 2018 - 2030 (USD Million)
  • Fig. 31 Continuous manufacturing process of tablets
  • Fig. 32 Continuous manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 33 Batch manufacturing process
  • Fig. 34 Batch manufacturing market, 2018 - 2030 (USD Million)
  • Fig. 35 Oral solid dose market, 2018 - 2030 (USD Million)
  • Fig. 36 Semi-solid dose market, 2018 - 2030 (USD Million)
  • Fig. 37 Liquid dose market, 2018 - 2030 (USD Million)
  • Fig. 38 Others market, 2018 - 2030 (USD Million)
  • Fig. 39 Japan CDMO market workflow outlook: Segment dashboard
  • Fig. 40 Japan CDMO market: Workflow movement analysis
  • Fig. 41 Japan clinical trial
  • Fig. 42 Clinical market, 2018 - 2030 (USD Million)
  • Fig. 43 Commercial market, 2018 - 2030 (USD Million)
  • Fig. 44 Japan CDMO market synthesis outlook: segment dashboard
  • Fig. 45 Japan CDMO market: synthesis movement analysis
  • Fig. 46 Oncology market, 2018 - 2030 (USD Million)
  • Fig. 47 Hormonal market, 2018 - 2030 (USD Million)
  • Fig. 48 Glaucoma market, 2018 - 2030 (USD Million)
  • Fig. 49 Cardiovascular disease market, 2018 - 2030 (USD Million)
  • Fig. 50 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 51 Others market, 2018 - 2030 (USD Million)
  • Fig. 52 Market participant categorization
  • Fig. 53 Heat map analysis
  • Fig. 54 Market participant categorization
目次
Product Code: GVR-4-68039-985-5

Japan CDMO Market Growth & Trends:

The Japan CDMO market is expected to reach USD 19.49 billion by 2030 and is projected to register a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for biopharmaceuticals, a high burden of diseases, and the rising geriatric population are some of the key growth drivers. Growing investments by various Contract Development and Manufacturing Organizations (CDMOs) for facility and service expansion are likely to boost the market over the forecast period.

In addition, increasing pharmaceutical R&D investments are driving the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in the R&D activities of pharmaceuticals. For instance, in March 2022, WuXi AppTec launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to accelerate the production of adeno-associated viruses for drugs in cell and gene therapy.

The increase in outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the Japan market.The trend of outsourcing activities in the pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.

Notably, regulatory authorities in Japan have accelerated approval for regenerative medical and gene therapy products. For instance, the adoption of the Pharmaceuticals and Medical Devices Act (PMD Act), 21st Century Cures Act, and PRIME (Priority Medicines) Initiative has helped the country improve access to regenerative medicines. Such initiatives by regulatory agencies are expected to improve the demand for the development and manufacturing of regenerative medicines in the country.

Japan CDMO Market Report Highlights:

  • The active pharmaceutical ingredient (API) segment dominated the market with a share of 81.2% in 2023. The segment growth is driven by competitive drug development and growing demand for end-to-end Contract Development & Manufacturing Organization (CDMO) services. In addition, advancements in API manufacturing, growth of the biopharmaceutical sector, and the increasing geriatric population are some of the key factors propelling segment growth
  • Based on workflow, the commercial segment held the largest market share in 2023, attributed to robust demand for pharmaceutical products, such as biosimilar medications, generic medications, and regenerative therapies. This is where commercial CDMOs may help by providing knowledge, saving time, and being cost-effective.
  • Based on application, the oncology segment dominated the test type market in 2023 with a revenue share of 35.3%, owing to the high cancer burden in the country. Approval of regenerative products and virotherapy for cancer treatment can further support market growth and the segment is further driven by increasing number of cancer cases globally. In addition, increasing pharmaceutical R&D investments, patent expirations, and demand for oncology drugs & biologic innovations are the factors driving the oncology segment growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product Type
    • 1.2.2. Work Flow Type
    • 1.2.3. Application
    • 1.2.4. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Type
    • 2.2.2. Work Flow Type
    • 2.2.3. Application
  • 2.3. Competitive Insights

Chapter 3. Japan CDMO Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Growing demand for Biopharmaceutical drugs in Japan
      • 3.2.1.2. High geriatric population and growing disease burden in Japan
      • 3.2.1.3. Low cost associated with Outsourcing Drug Manufacturing and Development services
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Limited outsourcing opted by big pharma companies
      • 3.2.2.2. Quality Issues While Outsourcing
  • 3.3. Japan CDMO Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Japan CDMO Market: Product Estimates & Trend Analysis

  • 4.1. Definitions and Scope
    • 4.1.1. API
    • 4.1.2. Drug Product
  • 4.2. Product Market Share, 2023 & 2030
  • 4.3. Segment Dashboard
  • 4.4. Japan CDMO Market Movement Analysis
  • 4.5. Japan CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
    • 4.5.1. API
      • 4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.2. Type
      • 4.5.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.2.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
      • 4.5.1.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.2.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
      • 4.5.1.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.2.4. Antibody Drug Conjugate (ADC)
      • 4.5.1.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.2.5. Others
      • 4.5.1.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.3. Synthesis
      • 4.5.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.3.2. Synthetic
      • 4.5.1.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.3.2.2. Solid
      • 4.5.1.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.3.2.3. Liquid
      • 4.5.1.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.3.3. Biotech
      • 4.5.1.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.4. Drug
      • 4.5.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.4.2. Innovative
      • 4.5.1.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.4.3. Generics
      • 4.5.1.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.5. Manufacturing
      • 4.5.1.5.1. Continuous manufacturing
      • 4.5.1.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.1.5.2. Batch manufacturing
      • 4.5.1.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.5.2. Drug Product
      • 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.2.2. Oral solid dose
      • 4.5.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.2.3. Semi-solid dose
      • 4.5.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.2.4. Liquid dose
      • 4.5.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
      • 4.5.2.5. Others
      • 4.5.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Japan CDMO Market: Workflow Estimates & Trend Analysis

  • 5.1. Definitions and Scope
    • 5.1.1. Clinical
    • 5.1.2. Commercial
  • 5.2. Segment Dashboard
  • 5.3. Japan CDMO Market Movement Analysis
  • 5.4. Japan CDMO Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
    • 5.4.1. Clinical
      • 5.4.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.4.2. Commercial
      • 5.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Japan CDMO Market: Application Estimates & Trend Analysis

  • 6.1. Definitions and Scope
    • 6.1.1. Oncology
      • 6.1.1.1. Small Molecule
      • 6.1.1.2. Biologics
    • 6.1.2. Infectious Diseases
    • 6.1.3. Neurological Disorders
    • 6.1.4. Cardiovascular Diseases
    • 6.1.5. Metabolic Disorders
    • 6.1.6. Autoimmune Diseases
    • 6.1.7. Respiratory Diseases
    • 6.1.8. Ophthalmology
    • 6.1.9. Gastrointestinal Disorders
    • 6.1.10. Hormonal Disorders
    • 6.1.11. Hematological Disorders
    • 6.1.12. Others
  • 6.2. Segment Dashboard
  • 6.3. Japan CDMO Market Movement Analysis
  • 6.4. Japan CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
    • 6.4.1. Oncology
      • 6.4.1.1. Market Estimates and forecast 2018 to 2030 (USD million)
      • 6.4.1.2. Small Molecule
      • 6.4.1.2.1. Market estimates and forecast 2018 to 2030 (USD million)
      • 6.4.1.3. Biologics
      • 6.4.1.3.1. Market estimates and forecast 2018 to 2030 (USD million)
    • 6.4.2. Infectious Diseases
      • 6.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.3. Neurological Disorders
      • 6.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.4. Cardiovascular Diseases
      • 6.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.5. Metabolic Disorders
      • 6.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.6. Autoimmune Diseases
      • 6.4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.7. Respiratory Diseases
      • 6.4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.8. Ophthalmology
      • 6.4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.9. Gastrointestinal Disorders
      • 6.4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.10. Hormonal Disorders
      • 6.4.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.11. Hematological Disorders
      • 6.4.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 6.4.12. Others
      • 6.4.12.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Vendor Landscape
  • 7.4. Market Participant Categorization
    • 7.4.1. List of key distributors and channel partners
    • 7.4.2. Key customers
    • 7.4.3. Key company market share analysis, 2023
    • 7.4.4. Lonza
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Product benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Thermo Fisher Scientific, Inc.
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Product benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Recipharm AB
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Product benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Laboratory Corporation of America Holdings (LabCorp)
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Product benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Catalent, Inc.
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Product benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. WuXi AppTec, Inc.
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Product benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Samsung Biologics
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Product benchmarking
      • 7.4.10.4. Strategic initiatives
    • 7.4.11. CordenPharma International
      • 7.4.11.1. Company overview
      • 7.4.11.2. Financial performance
      • 7.4.11.3. Product benchmarking
      • 7.4.11.4. Strategic initiatives
    • 7.4.12. Cambrex Corporation
      • 7.4.12.1. Company overview
      • 7.4.12.2. Financial performance
      • 7.4.12.3. Product benchmarking
      • 7.4.12.4. Strategic initiatives
    • 7.4.13. Bushu Pharmaceuticals Ltd.
      • 7.4.13.1. Company overview
      • 7.4.13.2. Financial performance
      • 7.4.13.3. Product benchmarking
      • 7.4.13.4. Strategic initiatives
    • 7.4.14. CMIC HOLDINGS Co., LTD.
      • 7.4.14.1. Company overview
      • 7.4.14.2. Financial performance
      • 7.4.14.3. Product benchmarking
      • 7.4.14.4. Strategic initiatives
    • 7.4.15. Nipro Corporation
      • 7.4.15.1. Company overview
      • 7.4.15.2. Financial performance
      • 7.4.15.3. Product benchmarking
      • 7.4.15.4. Strategic initiatives
    • 7.4.16. Sumitomo Chemical Company, Limited
      • 7.4.16.1. Company overview
      • 7.4.16.2. Financial performance
      • 7.4.16.3. Product benchmarking
      • 7.4.16.4. Strategic initiatives